Table III.
Associations between HPV16 infection, FHIT loss and clinicopathological characteristics in lung cancer.
| Characteristic | HPV16+ | HPV16− | P-value | FHIT loss+ | FHIT loss− | P-value |
|---|---|---|---|---|---|---|
| Non-cancer controls | 7 (6.36) | 103 (93.64) | <0.001 | 8 (7.27) | 102 (92.73) | <0.001 |
| Lung cancer cases | 67 (37.22) | 113 (62.78) | 80 (44.44) | 100 (55.56) | ||
| SCC | 45 (51.14) | 43 (48.86) | 0.006 | 53 (60.23) | 35 (39.77) | 0.003 |
| AC | 15 (26.79) | 41 (73.21) | 15 (26.79) | 41 (73.21) | ||
| SCLC | 7 (19.44) | 29 (80.56) | 12 (33.33) | 24 (66.67) | ||
| Cell differentiation | 0.052 | 0.007 | ||||
| Poor | 39 (45.88) | 46 (54.12) | 49 (57.65) | 36 (42.35) | ||
| Moderate | 21 (36.84) | 36 (63.16) | 22 (38.60) | 35 (61.40) | ||
| Well | 7 (18.42) | 31 (81.58) | 9 (23.68) | 29 (76.32) | ||
| TNM stage of tumors | 0.723 | 0.654 | ||||
| I+II | 43 (38.39) | 69 (61.61) | 45 (40.18) | 67 (59.82) | ||
| III+IV | 24 (35.29) | 44 (64.71) | 35 (51.47) | 33 (48.53) | ||
| Lymph node metastasis | 0.997 | 0.965 | ||||
| N0 | 36 (37.50) | 60 (62.50) | 42 (43.75) | 54 (56.25) | ||
| N1–3 | 31 (36.91) | 53 (63.09) | 38 (45.24) | 46 (54.76) | ||
| Smoking history | 0.033 | <0.001 | ||||
| Yes | 55 (44.35) | 69 (55.65) | 69 (55.65) | 55 (44.35) | ||
| No | 12 (21.43) | 44 (78.57) | 11 (19.64) | 45 (80.36) | ||
| Gender | 0.706 | 0.162 | ||||
| Male | 47 (37.01) | 80 (62.99) | 65 (51.18) | 62 (48.82) | ||
| Female | 20 (37.74) | 33 (62.26) | 15 (28.30) | 38 (71.70) | ||
| Age, years | 0.340 | 0.866 | ||||
| <55 | 32 (38.10) | 52 (61.90) | 39 (46.43) | 45 (53.57) | ||
| ≥55 | 35 (36.46) | 61 (63.54) | 41 (42.71) | 55 (57.29) |
HPV, human papillomavirus; FHIT, fragile histidine triad; SCC, squamous cell carcinoma; AC, adenocarcinoma; SCLC, small cell carcinoma; TNM, tumor-node-metastasis.